ADX71743, a Potent and Selective Negative Allosteric Modulator of Metabotropic Glutamate Receptor 7: In Vitro and In Vivo Characterization

@article{Kalinichev2013ADX71743AP,
  title={ADX71743, a Potent and Selective Negative Allosteric Modulator of Metabotropic Glutamate Receptor 7: In Vitro and In Vivo Characterization},
  author={M. Kalinichev and M. Rouillier and F. Girard and I. Royer-Urios and B. Bournique and T. Finn and D. Charvin and B. Campo and Emmanuel Le Poul and V. Mutel and S. Poli and S. Neale and T. Salt and R. Luetjens},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  year={2013},
  volume={344},
  pages={624 - 636}
}
  • M. Kalinichev, M. Rouillier, +11 authors R. Luetjens
  • Published 2013
  • Chemistry, Medicine
  • The Journal of Pharmacology and Experimental Therapeutics
  • Metabotropic glutamate receptor 7 (mGlu7) has been suggested to be a promising novel target for treatment of a range of disorders, including anxiety, post-traumatic stress disorder, depression, drug abuse, and schizophrenia. Here we characterized a potent and selective mGlu7 negative allosteric modulator (NAM) (+)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo[d]oxazol-4(5H)-one (ADX71743). In vitro, Schild plot analysis and reversibility tests at the target confirmed the NAM properties of the… CONTINUE READING
    Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs
    • 7
    • Highly Influenced
    • Open Access
    Group III Metabotropic Glutamate Receptors: Pharmacology, Physiology and Therapeutic Potential
    • 31

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 62 REFERENCES
    Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression
    • 55
    The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise?
    • 85
    • Open Access
    Context-Dependent Pharmacology Exhibited by Negative Allosteric Modulators of Metabotropic Glutamate Receptor 7
    • 70
    • Open Access
    Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
    • 102